Combined vitreoretinal-cataract system (VCS) is cleared for use in Canada New, proprietary technology is designed to deliver significant surgical and workflow efficiencies First innovation to be introduced from Alcon’s cutting-edge Unity portfolio of surgical equipment TORONTO / Jul 08, 2025 / Business Wire / Alcon , the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY ®... Read More

LumiThera’s photobiomodulation (PBM) device is the first and only technology that has demonstrated meaningful visual improvement with two years of treatments* in early and intermediate dry AMD patients 1,2 Nearly 200 million people globally live with dry AMD, a progressive disease with no cure, and a leading cause of blindness in developed nations 3,4 Alcon aims to expand PBM office-based treatment in approved markets,... Read More

Certification as a Top Employer in Canada issued by the Top Employers Institute People Strategy, Career Development, Rewards and Recognition, Purpose and Values, and Diversity & Inclusion noted as Alcon Canada’s top performance areas TORONTO / Jun 26, 2025 / Business Wire / Alcon , the global leader in eye care dedicated to helping people see brilliantly, today announced that Alcon Canada has been certified as a Top Employer... Read More

Clareon PanOptix Pro has half the light scatter of Clareon PanOptix 1-3,*,** PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics 1-4,*,**,† Clareon PanOptix Pro provides more uninterrupted light distribution across the full visual range, and is designed for better image contrast 1,††,‡ TORONTO / Jun 20, 2025 / Business Wire / Alcon... Read More

In pivotal Phase 3 trials, TRYPTYR demonstrated rapid natural tear production as early as Day 1 1-2 TRYPTYR is a first-in-class TRPM8 receptor agonist that rapidly stimulates natural tear production in patients with Dry Eye Disease (DED) 3 Approximately 38 million individuals in the U.S. are living with DED, yet less than 10% of diagnosed patients are being treated with a prescription product 4 GENEVA / May 28, 2025 /... Read More

First-quarter 2025 sales of $2.5 billion, in line on a reported basis, or up 3% constant currency 1 (cc), versus first-quarter 2024 First-quarter 2025 diluted EPS of $0.70; core diluted EPS 2 of $0.73 Generated $384 million cash from operations and $278 million free cash flow 3 Dividend of CHF 0.28 per share approved by shareholders at the Annual General Meeting on May 6, 2025 Launched rich pipeline of innovative products,... Read More

Shareholders approve all agenda items presented Deborah Di Sanzo elected as new member of the Board 2024 Compensation Report and Report on Non-Financial Matters approved in advisory votes GENEVA / May 06, 2025 / Business Wire / Alcon Inc . (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2025 Annual General Meeting... Read More

First-to-market innovations enhance efficiency, including HYPERVIT 30K, the world’s fastest vitrectomy probe executing 30,000 cuts per minute 1-3 Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye, supporting excellent patient care 4,*,† Inventory will begin shipping to Australia, Europe, Japan and the U.S. from May onwards GENEVA / Apr 25, 2025 / Business Wire / Alcon , the... Read More

Alcon welcomes its shareholders to its third in-person AGM Alcon Board of Directors proposes to elect Deborah Di Sanzo as a new Board member Proposed dividend of CHF 0.28 cash per share GENEVA / Apr 04, 2025 / Business Wire / Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 6, 2025. Alcon is pleased to welcome shareholders to its third in-person AGM since becoming an... Read More

Clareon PanOptix Pro provides unprecedented 94% light utilization, resulting in half the light scatter of Clareon PanOptix 1,2,§,* Clareon PanOptix Pro provides more uninterrupted light distribution across the full visual range, and is designed for better image contrast 1,† Commercially available in the U.S. in May, Clareon PanOptix Pro is the next generation of the world’s leading trifocal IOL 3-5,‡ GENEVA / Apr 02, 2025 /... Read More

Leverages Alcon’s global scale with Aurion’s cell therapy expertise to accelerate U.S. Phase 3 development in fall of 2025 Aurion’s lead asset received Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation from the U.S. Food and Drug Administration (FDA) Positions Alcon at the leading edge of biopharma applications in ophthalmology with the potential to advance the first-ever corneal cell... Read More

Clareon Vivity IOL provides an extended range of vision from distance to functional near with a monofocal visual disturbance profile 1-3 µ‖ Vivity, the world’s leading EDOF, is now available on Alcon’s Clareon material, providing presbyopia correction with exceptional † clarity and predictable refractive outcomes 1,4-7 CE Marked countries will begin commercial rollout of Clareon Vivity and Clareon Vivity Toric from early Q2... Read More

GENEVA / Mar 13, 2025 / Business Wire / Alco n (SIX/NYSE: ALC), the global leader in eye care, will host its 2025 Capital Markets Day on March 27, 2025, beginning at 8:00 a.m. CT. A live webcast of the event will be available at the following link: Click Here . Those wishing to participate should register and log on approximately 10 minutes before the start of the webcast. About Alcon Alcon helps people see brilliantly. As... Read More

TOTAL30 for Astigmatism, the first and only monthly replacement Water Gradient toric contact lens, 1-3 is now available in expanded parameters Features the same 95% fit success rate and innovative PRECISION BALANCE 8|4 technology 4* New expanded parameters help more astigmatic patients address unmet needs for comfort 5 and... Read More

Full-year 2024 sales of $9.8 billion, up 5%, or up 6% constant currency 1 (cc) Full-year 2024 diluted EPS of $2.05, up 5% on a reported basis, or up 11% cc; core diluted EPS 2 of $3.05 up 11% on a reported basis, or up 16% cc Generated record $2.1 billion of cash from operations in full-year 2024; record free cash flow 3 of $1.6 billion, up 120% Announced share repurchase authorization to offset dilution from associate... Read More

SYSTANE PRO Preservative-Free (PF) is the longest lasting dry eye drop in the SYSTANE portfolio 1 SYSTANE PRO PF is a one-of-a-kind multi-dose preservative-free triple action formula that hydrates, restores and protects all types of dry eyes 1 SYSTANE PRO PF will be showcased at SECO 2025 as the latest addition to the SYSTANE line of products, the #1 global consumer brand of artificial tears 2 GENEVA / Feb 24, 2025 /... Read More

New first-line laser treatment for the nearly 5 million Americans diagnosed with glaucoma 1,2 Automated device enables a streamlined workflow without a gonio lens or manual aiming 2 Voyager Direct Selective Laser Trabeculoplasty (DSLT) will be launched at the American Glaucoma Society annual meeting in Washington, D.C. GENEVA / Feb 19, 2025 / Business Wire / Alcon (SIX/NYSE: ALC), the global leader in eye care, dedicated to... Read More

GENEVA / Dec 31, 2024 / Business Wire / Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2025 J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 4:30 p.m. PST. A live webcast of the conference will be available at investor.alcon.com/news-and-events/events-and-presentations . About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we... Read More

Third-quarter 2024 sales of $2.4 billion, up 6% on a reported and constant currency 1 (cc) basis Third-quarter 2024 diluted EPS of $0.53, up 29%, or 32% cc; core diluted EPS 2 of $0.81, up 23%, or 25% cc Generated $1.6 billion of cash from operations in the first nine months of 2024; record free cash flow 3 of $1.3 billion, up $704 million, or 119% Ad Hoc Announcement Pursuant to Art. 53 LR GENEVA / Nov 12, 2024 / Business... Read More

PRECISION7, a new one-week replacement lens, provides 16 hours of outstanding comfort and precise vision, even on day 7 1 Features world’s first ACTIV-FLO System specially designed for one-week optimal performance 2 PRECISION7 broadens existing WaterInnovations portfolio, addressing the need for comfort and affordability when a daily disposable lens is not an option 1,3* GENEVA / Nov 07, 2024 / Business Wire / Alcon... Read More

Attendees can experience a first look at Voyager DSLT, Alcon’s new first-line laser therapy for glaucoma patients Alcon introduces new handheld gas delivery systems, UNIFEYE and UNIPEXY, optimizing convenience and accuracy for retina surgeons In addition, Alcon presents pivotal data for AR-15512 (acoltremon 0.003%)*, a prescription drug candidate undergoing FDA review for the treatment of dry eye FORT WORTH, Texas / Oct 15,... Read More

Record Q2 2024 sales of $2.5 billion, up 3%, or 6% constant currency 1 (cc) Q2 2024 diluted EPS of $0.45, up 32%, or 47% cc; core diluted EPS 2 of $0.74, up 7%, or 15% cc H1 2024 cash from operations of $871 million; free cash flow 3 of $667 million, up $478 million, or 253% Received U.S. FDA clearance of Unity VCS/CS and PDUFA date for AR-15512 of May 30 th , 2025 Ad Hoc Announcement Pursuant to Art. 53 LR GENEVA / Aug 20,... Read More

Combined vitreoretinal-cataract system (VCS) and standalone cataract system (CS) are cleared for use in the U.S. New, proprietary technologies designed to deliver transformative surgical innovation Alcon to immediately begin collecting real-world user experience in the U.S. prior to broad commercialization in 2025 First innovations to be introduced from Alcon’s cutting-edge Unity portfolio of surgical equipment Ad Hoc... Read More

First-quarter 2024 sales of $2.4 billion, up 5%, or 7% constant currency 1 (cc) First-quarter 2024 diluted EPS of $0.50, up 43%, or 62% cc; core diluted EPS 2 of $0.78 up 11%, or 21% cc First-quarter 2024 cash from operations of $341 million; free cash flow 3 of $229 million, up $248 million year-over year Dividend of CHF 0.24 per share approved by shareholders at the Annual General Meeting on May 8, 2024 GENEVA / May 13,... Read More

Shareholders approve dividend of CHF 0.24 per share Shareholders confirm F. Michael Ball as member and Chair of the Board of Directors as well as the other members who all stood for re-election Shareholders approve the 2023 Non-Financial Matters Report in an advisory vote Shareholders approve the Board and Executive Committee compensation in separate binding votes GENEVA / May 08, 2024 / Business Wire / Alcon Inc. (SIX/NYSE:... Read More

Alcon welcomes its shareholders to its second in-person AGM In addition to the regular agenda items, shareholders to vote on the Report on Non-Financial Matters Proposed dividend of CHF 0.24 cash per share GENEVA / Apr 07, 2024 / Business Wire / Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 8, 2024. Alcon is pleased to welcome shareholders to its second in-person AGM... Read More

Vivity is the most implanted extended depth of focus (EDOF) intraocular lens (IOL) globally 1 Milestone underscores the impact of Vivity’s first-of-its-kind, patented wavefront-shaping technology, which simplifies presbyopia correction for surgeons and patients 2,3 Vivity demonstrates excellent outcomes, with real-world Vivity Registry data from more than 900 cataract patients, including patients with certain mild... Read More

Q4 2023 sales of $2.3 billion, up 8%, or 10% constant currency (1) (cc) Q4 2023 diluted EPS of $0.86, compared to a loss in the prior year (3) ; core diluted EPS (2) of $0.70 up 67%, or 78% cc FY 2023 sales of $9.4 billion, up 8%, or 10% cc FY 2023 diluted EPS of $1.96, up 188%; core diluted EPS of $2.74, up 22%, or 33% cc FY 2024 outlook: 6% to 8% cc sales growth, 13% to 16% cc core diluted EPS growth Ad Hoc Announcement... Read More

The first and only monthly Water Gradient multifocal contact lens that feels like nothing – even at day 30 1 Provides excellent visual acuity at all distances, near through far, with Alcon’s proven Precision Profile design that fits in two easy steps, delivering 96% fit success 2-4 New TOTAL30 Multifocal contact lenses will... Read More

AR-15512, a topical transient receptor potential melastatin 8 (TRPM8) agonist, is a first-in-class product candidate for the treatment of the signs and symptoms of dry eye disease In both pivotal efficacy and safety studies (COMET-2 and COMET-3), the primary endpoint was achieved (p <0.0001) Dry eye affects an estimated 38 million people in the U.S. and less than 10% of diagnosed patients are treated with a prescription... Read More

GENEVA / Dec 27, 2023 / Business Wire / Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2024 J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. PST. A live webcast of the conference will be available at investor.alcon.com/news-and-events/events-and-presentations . About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years,... Read More

Third quarter 2023 sales of $2.3 billion, up 8%, or 9% constant currency (1) (cc) Third quarter 2023 diluted EPS of $0.41, up 78%, or up 97% cc; core diluted EPS (2) of $0.66 up 32%, or 41% cc Generated $937 million of cash from operating activities and $592 million of free cash flow (3) in the first nine months of 2023 Ad Hoc Announcement Pursuant to Art. 53 LR GENEVA / Nov 14, 2023 / Business Wire / Alcon (SIX/NYSE:ALC),... Read More

Clareon Vivity is the first and only non-diffractive extended depth of focus (EDOF) IOL with the wavefront-shaping X-WAVE Technology on Alcon’s most advanced lens platform 1-6 Clareon Vivity joins Alcon’s existing portfolio of IOLs for cataract patients who are looking for presbyopia correction with a monofocal-like visual disturbance profile 1-11 Clareon Vivity is designed to provide a superior halo profile compared to... Read More

Alcon announces full U.S. commercial availability of cloud-based cataract planner, building on its leading image-guided clinic to OR connectivity Attendees can experience digital, customer-centric technologies and patient engagement tools at Alcon booth #639 Key data and events at AAO will highlight the benefits of Alcon innovation across cataract, glaucoma, refractive and retina FORT WORTH, Texas / Oct 30, 2023 / Business... Read More

The first and only monthly Water Gradient multifocal contact lens — feels like nothing even at day 30 1 Provides excellent visual acuity at all distances, near through far, with Alcon’s proven Precision Profile design that fits in two easy steps, delivering 96% fit success 2-4 New lenses will help address the vision and comfort needs of the global multifocal market, which is growing faster than the overall contact lens... Read More

Alcon Vivity Registry continues to demonstrate excellent outcomes with AcrySof IQ Vivity and AcrySof IQ Vivity Toric, the first and only PCIOL + with wavefront-shaping technology World-renowned surgeons will present new registry data at #ESCRS2023, including data on rates of visual disturbances 1,2 Registry monitored 900+ cataract patients post-surgery, including those with certain mild comorbidities GENEVA / Sep 09, 2023 /... Read More

Alcon innovations featured in more than 75 abstracts across cataract, refractive, visualization and ocular health 1 Clinical data presentations and sponsored symposia to highlight the efficacy of Alcon’s intraocular lens and surgical equipment portfolio Booth activations to feature expert discussions and demos with Alcon’s latest innovation, including wavelight plus, the next generation in refractive surgery, which has now... Read More

Second quarter 2023 sales of $2.4 billion, up 9%, or 12% constant currency (1) (cc) Second quarter 2023 diluted EPS of $0.34, up 13%, or up 34% cc; core diluted EPS (2) of $0.69 up 10%, or 19% cc Based on strong operational performance and improved outlook, Company raises full year 2023 sales and core diluted EPS guidance GENEVA / Aug 15, 2023 / Business Wire / Alcon (SIX/NYSE:ALC), the global leader in eye care, reported... Read More

Alcon in Action, a company-wide community volunteerism initiative, reinforces the company’s year-round commitment to community engagement and bolsters Alcon’s aspiration to improve lives and strengthen communities Thousands of company associates across 30 countries participate in the initiative that inspires associates to make direct, positive impacts in their local communities Follow the activities on Alcon Facebook,... Read More

First quarter 2023 sales of $2.3 billion, up 7%, or 11% constant currency (1) (cc) First quarter 2023 diluted EPS of $0.35, up 3%, or up 26% cc; core diluted EPS (2) of $0.70 up 3%, or 14% cc Dividend of CHF 0.21 per share approved by shareholders at the Annual General Meeting on May 5, 2023 Raised full year 2023 cc sales and core diluted EPS growth outlook Ad Hoc Announcement Pursuant to Art. 53 LR GENEVA / May 09, 2023 /... Read More

An investigator led, non-interventional study evaluated the performance of two monofocal intraocular lenses (IOLs) in 620 eyes of 310 cataract patients in the U.S. 1 Clareon monofocal IOL provides excellent distance vision, and intermediate vision that is non-inferior to TECNIS Eyhance * monofocal IOL 1,2 The full Clareon Collection also offers surgeons clinically-proven extended depth of focus and presbyopia-correcting IOL... Read More

Shareholders approve dividend of CHF 0.21 per share Shareholders confirm F. Michael Ball as member and Chair of the Board of Directors as well as the other members who all stood for re-election Shareholders approve all other proposals of the Board of Directors, including the amendment of the Articles of Incorporation, the 2022 Compensation Report in an advisory vote, as well as the Board and Executive Committee compensation... Read More

Alcon innovations featured in approximately 180 abstracts across cataract, glaucoma, refractive, visualization and ocular health 1 New data demonstrates comparable range of vision and intermediate visual acuity between Clareon monofocal IOL and TECNIS Eyhance* monofocal IOL 2 Alcon advances next-generation workflow connectivity, integrating ARGOS Biometer with Image Guidance and newly available NGENUITY 1.5 3-8 FORT WORTH,... Read More

Alcon welcomes its shareholders to its first in-person AGM In addition to the regular agenda items, Alcon Board of Directors proposes to amend the Articles of Incorporation to conform to recent Swiss corporate law reform Proposed dividend of CHF 0.21 cash per share GENEVA / Mar 29, 2023 / Business Wire / Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 5, 2023. Alcon is... Read More

Silver Anthem Award Recognizes The Lens as Best Special Workforce Initiative: Health GENEVA / Mar 23, 2023 / Business Wire / Alcon , the global leader in eye care dedicated to helping people see brilliantly, today announced that its interactive compliance training video experience, The Lens, has been named Best Special Workforce Initiative: Health in the 2 nd Annual Anthem Awards. Launched in 2021 by The Webby Awards, The... Read More

GENEVA / Mar 20, 2023 / Business Wire / Alcon (SIX/NYSE: ALC), the global leader in eye care, will host its 2023 Capital Markets Day on March 30, 2023 beginning at 8:00 a.m. CT. A live webcast of the event will be available at https://investor.alcon.com/news-and-events/events-and-presentations/default.aspx . About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75... Read More

FORT WORTH / Mar 01, 2023 / Business Wire / Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will unveil its latest innovations and expansive suite of vision care products at the SECO International meeting in Atlanta, Georgia. Alcon will debut TOTAL30 ® for Astigmatism, the first and only reusable Water Gradient toric lens on the market, 1 now available to Eye Care... Read More

GENEVA / Feb 27, 2023 / Business Wire / Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve months ended December 31, 2022. For the fourth quarter of 2022, sales were $2.2 billion, an increase of 1% on a reported basis and 7% on a constant currency basis (1) , as compared to the same quarter of the previous year. Alcon reported a loss per share of $0.20 and core... Read More

GENEVA / Feb 12, 2023 / Business Wire / Alcon Inc. ("Alcon") (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has entered into a settlement agreement with J&J Surgical Vision, Inc. to resolve their pending legal proceedings relating to femtosecond laser assisted cataract surgery devices, including Alcon’s LenSx ® device, which Alcon acquired as part of its... Read More

The first reusable, Water Gradient lens for astigmatic contact lens wearers Reusable toric market is greater than $1.2B and growing 1 Commercially available in the U.S. and Europe beginning in early 2023 Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced plans to launch TOTAL30 ® for Astigmatism, the first-and-only reusable contact lens with Water Gradient... Read More

Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2023 J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 11:15 a.m. PST. A live webcast of the conference will be available at investor.alcon.com/news-and-events/events-and-presentations . About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of... Read More